A further analysis of data from the Phase 2 OCEAN(a)-DOSE trial has shown that olpasiran reduces Lp(a) in patients with elevated levels, irrespective of apo(a) isoform size. Small apo(a) isoforms have fewer Kringle IV-2 (KIV-2) repeats and are typically associated with higher Lp(a) concentrations compared with large apo(a) isoforms. Over 80% of people carry two different sized apo(a) isoforms, each inherited from one parent, and the smallest isoform typically predominates in plasma.
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
